Clinical trials: Tumor Pancreas
Cancer of Pancreas, Chemotherapy Effect
Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment.
- Conditions
- Cancer of Pancreas, Chemotherapy Effect, Metastatic Pancreatic Cancer
- Trial name
- NCT04769414
- Testing
- Gemcitabine fluorouracil
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Menoufia University
Pancreatic Adenocarcinoma
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
The purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records.
- Trial name
- NCT05287347
- Testing
- Blood Specimen
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Neoplasms, Lung Neoplasms
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to…
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms
- Trial name
- N1 (NCT02900248)
- Testing
- Provider determined
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CureOne
Congenital Hyperinsulinism, Insulinoma
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI).
- Trial name
- NCT02021604
- Testing
- Fluorodopa F 18
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Cook Children's Health Care System
Neuroendocrine Tumors, Neoplasms
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug…
- Conditions
- Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
- Trial name
- NCT02943733
- Testing
- TAS-102, Temozolomide, Filgrastim
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
This pilot phase I trial studies the side effects of gemcitabine hydrochloride, nab-paclitaxel, metformin hydrochloride, and a standardized dietary supplement in treating patients with pancreatic cancer that cannot be removed by…
- Conditions
- Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02336087
- Testing
- Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Neuroendocrine Cancer
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
- Trial name
- NCT02318784
- Testing
- Carfilzomib
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Pancreatic Cancer, Periampullary Cancer
Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using USPIO MRI
Adenocarcinoma's of the pancreas and periampullary region (distal bile duct, ampulla of Vater and duodenum) are cancers with a poor survival.
- Trial name
- NANO-PANC (NCT04311047)
- Testing
- USPIO-enhanced MRI
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Radboud University Medical Center
Pancreatic Neuroendocrine Tumors
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
- Trial name
- NCT02842749
- Testing
- everolimus
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study Looking at Whether a Nutritional Composition Can Help People With Pancreatic Cancer Stay Stronger and Better Tolerate Chemotherapy
The HEXCARE-PDAC study is a Phase III, randomized, double-blind, controlled, multicenter trial evaluating the effectiveness of a cancer-specific oral nutritional supplement in preserving skeletal muscle mass and improving…
- Trial name
- HEXCARE-PDAC (NCT07870421)
- Testing
- A novel cancer-specific high energy high protein medical nutrition solution, A commercially available isocaloric isonitrogenous medical nutritional solution.
- Volunteers
- 216 people
- Sponsor
- Nutricia Research
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma
Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer
This is an open-label, non-randomized Phase II study to evaluate immunochemotherapy in patients with R0 OR R1-resected pancreatic cancer.
- Trial name
- ATIP (NCT00395252)
- Testing
- Cetuximab (Erbitux®) and Gemcitabine
- Where
- 8 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Carmen Schade-Brittinger
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Locally Advanced Pancreatic Cancer
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
The purpose of the study is to determine the safety of radiofrequency ablation of locally advanced pancreatic cancer that can not be surgically removed with the current standard procedures.
- Trial name
- RFA of LAPC (NCT01628458)
- Testing
- radiofrequency ablation (RFA)
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- UMC Utrecht
Pancreatic Neoplasms
Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer
Given the dismal prognosis of pancreatic cancer, detecting liver metastases early can avoid inappropriate therapy with the associated substantial risks, long-term hospital admissions and high costs, but without survival benefit.
- Trial name
- DIA-PANC (NCT03469726)
- Testing
- Contrast-enhanced Diffusion-weighted MRI
- Where
- 7 sites in Greece, Netherlands and 2 more
- Volunteers
- 465 people
- Sponsor
- Radboud University Medical Center
Pancreatic Cancer, Pancreatic Neoplasms
Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer
The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related…
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Periampullary Carcinoma, Pancreatic Surgery
- Trial name
- POWR-PaC (NCT07772258)
- Testing
- Corsano CardioWatch, Prehab4Cancer Programme
- Volunteers
- 120 people
- Sponsor
- Manchester University NHS Foundation Trust
Pain, Cancer Pain
PENS or TENS for Pain in Pancreatic Cancer
This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with pancreatic cancer.
- Conditions
- Pain, Cancer Pain, Pancreatic Cancer
- Trial name
- NCT03331055
- Testing
- PENS, TENS
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Pancreatic Cancer
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT01218880
- Testing
- M2ES 7.5mg, M2ES 15mg, M2ES 30mg
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Metastatic Pancreatic Cancer
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
The majority patients diagnosed with pancreatic cancer have metastatic disease at the time of diagnosis. The prognosis is extremely poor with a 5-year survival rate of less than 5%.
- Trial name
- PACT-ACT-v6 (NCT02707159)
- Testing
- Nab paclitaxel / gemcitabine
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Helse Stavanger HF
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.